DISEASE: Lung: Non Small Cell
Select a REGIMEN:
CAMP
CAP
CBDCA+VP-16
CDDP + VP-16
FED
MVP
NVB[Navelbine(R)]-30
NVB[Navelbine(R)]-15
NVB-30+CDDP
NVB-15+CDDP
PVP-16
VIP(ICE)-2
DISEASE: Lung: Non Small Cell
REGIMEN: CAMP
CYCLOPHOSPHAMIDE [CTX] 300 mg/m2 IV...D1,8
DOXORUBICIN [DOX] 20 mg/m2 IV...D1,8
Caution: Monitor cumulative dose (cardiac toxicity)
METHOTREXATE [MTX] 15 mg/m2 IV...D1,8
PROCARBAZINE [PCB] 100 mg/m2 per day
PO...D1-10
CYCLE: 28 days
REFER: Bitran JD, et al: CANCER TREAT REP 1976; 60:1225-1230.
DISEASE: Lung: Non Small Cell
REGIMEN: CAP
CYCLOPHOSPHAMIDE [CTX] 400 mg/m2 IV...D1
DOXORUBICIN [DOX] 40 mg/m2 IV...D1
Caution: Monitor cumulative dose (cardiac toxicity)
CISPLATIN [CDDP] 60 mg/m2 IV...D1
CYCLE: 28 days
REFER: Eagan RT, et al: CANCER TREAT REP 1979; 63:1589-1591.
DISEASE: Lung: Non Small Cell
REGIMEN: CBDCA+VP-16
CYCLE: 28 days
REFER: Klastersky JP: J CLIN ONCOL 1990; 8:1556-1562.
DISEASE: Lung: Non Small Cell
REGIMEN: CDDP + VP-16
CISPLATIN [CDDP] 60 mg/m2 IV...D1
ETOPOSIDE [VP-16] 120 mg/m2
IV...D4,6,8 "or D3,5,7"
CYCLE: 21-28 days
REFER: Longeval E, et al: CANCER 1982; 50:2751-2756.
DISEASE: Lung: Non Small Cell
REGIMEN: FED
CISPLATIN [CDDP] 100 mg/m2 IV/over
3-4 hrs...D1
ETOPOSIDE [VP-16] 80 mg/m2 per day
IV...D2,3,4
FLUOROURACIL [5-FU] 960 mg/m2 per day x
3 CIV...D2,3,4
(2880 mg/m2 total)
CYCLE: 3 weeks
REFER: Sridhar KS, et al: SEMIN IN SURG ONCOL 1993; 9:114-119.
DISEASE: Lung: Non Small Cell
REGIMEN: MVP
MITOMYCIN C [MITC] 10 mg/m2 I...D1
Caution: Monitor cumulative dose (marrow toxicity,
hemolytic uremic syndrome)
VINBLASTINE [VLB] 6 mg/m2 IV...D1
CISPLATIN [CDDP] 40 mg/m2 IV...D1
CYCLE: 21 days
REFER: Bonomi PD, et al: J CLIN ONCOL 1989; 7:1602-1613.
DISEASE: Lung: Non Small Cell
REGIMEN: NVB[Navelbine(R)]-30
VINORELBINE [NVB] 30 mg/m2
IV...weekly
Use 30mg/m2 when granulocytes >= 1500; down dose to 15mg/m2
when granulocytes 1000-1499.
CYCLE: None
REFER: LeChevalier T, et al: J CLIN ONCOL 1994; 12:360-367.
DISEASE: Lung: Non Small Cell
REGIMEN: NVB[Navelbine(R)]-15
VINORELBINE [NVB] 15 mg/m2
IV...weekly
Use 15mg/m2 when granulocytes 1000-1499; no NVB when
granulocytes < 1000.
CYCLE: None
REFER: LeChevalier T, et al: J CLIN ONCOL 1994; 12:360-367..
DISEASE: Lung: Non Small Cell
REGIMEN: NVB-30+CDDP
VINORELBINE [NVB] 30 mg/m2
IV...weekly
Use 30mg/m2 when granulocytes >= 1500; down dose to 15mg/m2
when granulocytes 1000-1499.
CISPLATIN [CDDP] 120 mg/m2
IV...D1,29 then q6wks
CYCLE: None
REFER: LeChevalier T, et al: J CLIN ONCOL 1994; 12:360-367..
DISEASE: Lung: Non Small Cell
REGIMEN: NVB-15+CDDP
VINORELBINE [NVB] 15 mg/m2
IV...weekly
Use 15mg/m2 when granulocytes 1000-1499; no NVB when
granulocytes < 1000.
CISPLATIN [CDDP] 120 mg/m2
IV...D1,29 then q6wks
CYCLE: None
REFER: LeChevalier T, et al: J CLIN ONCOL 1994; 12:360-367..
DISEASE: Lung: Non Small Cell
REGIMEN: PVP-16
CYCLE: 21-28 days
REFER: Klastersky J: SEMIN IN ONCOL 1986; 13(Suppl 3):104-114.
DISEASE: Lung: Non Small Cell
REGIMEN: VIP(ICE)-2
IFOSFAMIDE [IFF] 1 - 1.2 g/m2 per
day IV...D1-3
with MESNA
CISPLATIN [CDDP] 100 mg/m2 IV...D1,8
ETOPOSIDE [VP-16] 60 - 75 mg/m2 per
day IV...D1-3
CYCLE: 28 days
REFER: Perez EA, et al: PROC ASCO 1992; 11:314.
|
Medicine OnLine and UltiTech have no liability for content or goods on the Internet except as set forth in the Terms and Conditions of service.
Please read the Disclaimer of Warranties before using information contained in this section.
© Copyright 1995-2000 UltiTech, Inc. All Rights Reserved.
|
